MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.08
-0.15
-2.07%
After Hours: 7.26 +0.18 +2.54% 18:10 07/15 EDT
OPEN
7.30
PREV CLOSE
7.23
HIGH
7.36
LOW
6.98
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
8.78
52 WEEK LOW
3.290
MARKET CAP
513.23M
P/E (TTM)
-6.2699
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRBP stock price target is 25.71 with a high estimate of 40.00 and a low estimate of 17.00.

EPS

CRBP News

More
Cannabis Stock Gainers And Losers From July 13, 2020
Gainers Halo Labs (OTC: AGEEF) shares closed up 16.5% at $0.09 Harvest Health (OTC: HRVSF) shares closed up 15.31% at $1.08
Benzinga · 2d ago
Corbus Pharmaceuticals appoints George Golumbeski to its board
Corbus Pharmaceuticals (CRBP -1.2%) appoints George Golumbeski, Ph.D., to its Board of Directors. Dr. Golumbeski formerly led corporate and business develo
seekingalpha · 07/08 19:30
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
GlobeNewswire · 07/08 13:05
Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock?
Insider Monkey · 07/06 02:58
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Top Marijuana Stocks on the NASDAQ for July 2020
The marijuana industry includes companies directly related to the research, development, and distribution of cannabis products, as well as companies that indirectly support these operations. As a growing number of U.S. states and countries around the world le
Investopedia · 06/30 18:07
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
GlobeNewswire · 06/29 13:05
Corbus Pharmaceuticals Highlights Presentation Of Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes At 6th Systemic Sclerosis World E-Congress
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label extension study ACR
Benzinga · 06/29 12:10

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
More

Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.